We found that blocking the IL-6 or TNF-α pathway with tocilizumab or TNF-α inhibitors, respectively, significantly reduced serum hepcidin-25 levels and improved anemia and disease activity in RA patients, indicating that these cytokines are involved in both hepcidin production and the pathogenesis of RA-anemia. Here, TNF is linked to anemia.